Accelerant Holdings: 149% EBITDA Growth Meets Non-GAAP Opacity and a CFO Selling Into Strength
A two-sided insurance risk exchange with SaaS-like economics serving 265 MGAs across 22 countries. The platform works. The financial reporting is another matter.
FY2025 (est.), +61% TTM growth
Existing members grew $1B TTM
$105M headline included $39M gains
Only net seller among 10 insiders
Accelerant Holdings went public in 2025 and immediately posted numbers that would make any SaaS founder envious: 135% net revenue retention, an 8% platform take rate expanding to higher levels, 70% EBITDA margins in its core Exchange Services segment, and a member pipeline exceeding $3 billion in annualized premium. The two-sided risk exchange connecting specialty insurance MGAs with institutional risk capital is genuinely innovative.
The financial reporting, however, demands careful parsing. Adjusted EBITDA grew 149% year-over-year in Q3 2025, but 37% of the headline figure came from irregular investment gains. FY2026 guidance of $269M EBITDA is essentially flat versus FY2025 when those gains are excluded. The CFO is the only insider who has reduced his equity position. And a single PE-backed insurer, Hadron, accounted for 54% of third-party premium.
Our 5-lens analysis ran two frontier AI models through the full disclosure stack, generating adversarial debates that probed each tension point. The result: a platform with structural advantages and a financial reporting framework that obscures them.
Want the full 5-lens analysis with signal assessments and model debates?
Opus + Sonnet ensemble. 5 lenses. 7 signals. 5 debates. Full evidence citations.
Signal Assessments
Multiple non-GAAP layers obscure true profitability. $39M investment gains in Q3 EBITDA. No GAAP guidance reconciliation.
8% fee rate and 135% NRR are structurally strong but only 2 quarters of public data exist. EBITDA growth lags premium growth.
$547M cash provides buffer, but model depends on continuous third-party risk capital. Hadron at 54% of third-party premium.
Capital-light transition to third-party insurers is strategically sound. $293M IPO SBC creates dilution pipeline.
Co-founders strongly aligned with fresh RSU grants. CFO is the sole net seller among 10 insiders.
22-country insurance operations with clean record. Lloyd's partnership adds credibility. Regulatory friction slows transitions.
Key Findings
The Platform Economics Are Real, but the Reporting Obscures Them
Exchange Services earns an 8% fee on all premium flowing through the exchange, generating 70% EBITDA margins. This is the core value proposition, and it works regardless of whether business flows through owned or third-party insurers. The take rate expanded from 7.1% to 8.0% year-over-year due to geographic mix shift toward higher-fee US/Canada contracts.
The problem is that this structural strength is buried under a three-segment reporting structure where management is deliberately shrinking one segment (Underwriting), including volatile investment gains in another (MGA Operations), and the consolidated picture requires non-GAAP adjustments to be interpretable.
CFO Selling Pattern Creates a Governance Overhang
Among 10 insiders with Form 4 filings, CFO Jay Green is the only one who has been a net seller, disposing of 229,262 shares. Every co-founder received new RSU grants in March 2026 with 4-year vesting schedules. The absence of any 10b5-1 pre-planned trading program makes Green's selling appear discretionary.
Discovery context flagged a potential CFO departure. No formal announcement has been filed as of March 2026, but the selling pattern combined with that context warrants close monitoring. At a newly public company still establishing financial reporting credibility, CFO continuity is particularly important.
Hadron Concentration Is Declining but Remains Material
PE-backed insurer Hadron (Altamont Capital) accounted for 54% of third-party insurer premium in Q3 2025, down from 58% the previous quarter. Management targets below 33% by Q4 2026 and has signed 17 total third-party insurers, including a Lloyd's of London facility and Ozark Specialty. The roadmap to diversification is credible, but execution risk remains.
Member Growth Machine Is the Crown Jewel
265 MGA members, 17 added in Q3 alone, with a record pipeline of $3B+ annualized premium. The 135% net revenue retention means existing members grew premiums by approximately $1 billion in the trailing 12 months. 90 new insurance products launched in the past year. This organic growth engine is the foundation of the entire platform thesis.
Where Models Disagreed
Is Non-GAAP Reporting Appropriate or Obfuscating?
Opus Position
Reporting is typical for newly public insurance platforms with large IPO-related charges. The 8% take rate is transparent and verifiable. Individual adjustments are each defensible.
Sonnet Position
The sheer volume of adjustments ($1.45B in Q3 alone) and refusal to reconcile GAAP guidance crosses from helpful to obfuscating. Including investment gains in EBITDA is particularly aggressive.
Is CFO Selling Meaningful or Routine Diversification?
Opus Position
CFO selling post-IPO is common. Without knowing Green's total equity position, 229K shares may represent a small fraction of total holdings.
Sonnet Position
Being the only seller among 10 insiders at a 149% EBITDA growth company is statistically notable. Combined with potential departure context, it demands attention.
Cross-Lens Convergence
Platform Economics Validated Across Lenses
Gravy Gauge and Stress Scanner independently confirmed the 8% take rate, 70% Exchange Services margins, and 135% NRR as structurally durable. The two-sided platform creates real network effects.
Hadron Concentration Flagged by Three Lenses
Fugazi Filter (related party risk), Gravy Gauge (revenue concentration), and Stress Scanner (counterparty risk) all independently identified Hadron/Altamont as a material watchpoint. Concentration declining but still at 54%.
CFO Signal Amplified Across Governance Lenses
Both Fugazi Filter and Insider Investigator flagged the CFO selling pattern as anomalous. At a company establishing post-IPO accounting credibility, CFO alignment is particularly important.
What to Watch
Any 8-K filing regarding officer changes. A CFO departure at a newly public company with complex multi-segment accounting would be the highest-impact governance event.
Currently 54% of third-party insurer premium. Management targets below 33% by Q4 2026. Failure to diversify on schedule would upgrade counterparty risk assessment.
Q3 2025 included $39M investment gains (37% of headline). If FY2026 EBITDA continues to rely on irregular gains to meet guidance, accounting integrity concern would escalate.
Currently 50-51% (management targets low 50s). Sustained above 55% would signal underwriting deterioration and erode the value proposition for risk capital partners.
Bottom Line
HIGHER SCRUTINY
Accelerant operates a genuinely innovative insurance platform with durable fee economics and strong organic growth. The 8% take rate, 135% NRR, and 70% Exchange Services EBITDA margins are real competitive advantages. However, the financial reporting complexity, embedded investment gains in EBITDA, CFO selling anomaly, and Hadron concentration collectively demand elevated diligence before the investment case can be validated.
Path to More Favorable Assessment
- • FY2026 EBITDA meets guidance without relying on investment gains
- • Hadron concentration below 33% by Q4 2026
- • CFO position stabilizes (no departure or smooth transition)
- • GAAP reconciliation provided for forward guidance
- • Gross loss ratio sustained in low 50s through a full year
Path to Less Favorable Assessment
- • CFO departure without credible replacement
- • Continued reliance on investment gains in EBITDA
- • Hadron exits or reduces participation pre-diversification
- • Gross loss ratio sustained above 55%
- • NRR compression below 120%
This analysis is for educational purposes only — it is not a recommendation to buy or sell any security.
Public Sources Used
- • Annual Report (10-K) — FY2025
- • Quarterly Report (10-Q) — Q3 2025
- • Quarterly Report (10-Q) — Q2 2025
- • Current Report (8-K) — Q4/FY2025 Earnings (Feb 2026)
- • Current Report (8-K) — Q3 2025 Earnings
- • Current Report (8-K) — Q2 2025 Earnings
- • Q3 2025 Earnings Call Transcript
- • Q2 2025 Earnings Call Transcript
- • Form 4 Insider Transaction Filings (20 filings, Jul 2025 - Mar 2026)
Full Analysis with Signal Breakdowns
Explore the complete 5-lens assessment including debate transcripts, evidence citations, and monitoring triggers.
View ARX Analysis